| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Departments of Epidemiology [C. A. H., S. E. H., D. S., G. A. C., W. C. W., D. J. H.], Nutrition [W. C. W.], Environmental Health [F. E. S., K. T. K.], Cancer Cell Biology [K. T. K.], and Biostatistics [D. S.], and Harvard Center for Cancer Prevention [K. T. K., D. J. H.], Harvard School of Public Health, and Channing Laboratory, Department of Medicine, Brigham and Womens Hospital [S. E. H., G. A. C., W. C. W., F. E. S., K. T. K., D. J. H.], Harvard Medical School, Boston, Massachusetts 02115
The A2 allele of CYP17 has been associated with polycystic ovarian syndrome, elevated levels of certain steroid hormones in premenopausal women, and increased breast cancer risk. We prospectively assessed the association between the A2 allele of CYP17 and breast cancer risk in a case-control study nested within the Nurses Health Study cohort. We also evaluated associations between this CYP17 genotype and plasma steroid hormone levels among postmenopausal controls not using hormone replacement to assess the biological significance of this genetic variant. Women with the A2 allele were not at an increased risk of incident breast cancer [OR (odds ratio), 0.85; 95% CI (confidence interval), 0.651.12] or advanced breast cancer (OR, 0.84; 95% CI, 0.541.32). We did observe evidence that the inverse association of late age at menarche with breast cancer may be modified by the CYP17 A2 allele. The protective effect of later age at menarche was only observed among women without the A2 allele (A1/A1 genotype: for age at menarche
13 versus <13; OR, 0.57; 95% CI, 0.360.90; A1/A2 and A2/A2 genotypes: OR, 1.05; 95% CI, 0.761.45; P for interaction = 0.07). Among controls, we found women with the A2/A2 genotype to have elevated levels of estrone (+14.3%, P = 0.01), estradiol (+13.8%, P = 0.08), testosterone (+8.6%, P = 0.34), androstenedione (+17.1%, P = 0.06), dehydroepiandrosterone (+14.4%, P = 0.02), and dehydroepiandrosterone sulfate (+7.2%, P = 0.26) compared with women with the A1/A1 genotype. These data suggest that the A2 allele of CYP17 modifies endogenous hormone levels, but is not a strong independent risk factor for breast cancer.
This article has been cited by other articles:
![]() |
Y. Chen, M. D. Gammon, S. L. Teitelbaum, J. A. Britton, M. B. Terry, S. Shantakumar, S. M. Eng, Q. Wang, I. Gurvich, A. I. Neugut, et al. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project Carcinogenesis, April 1, 2008; 29(4): 766 - 771. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Campbell, L. Edwards, J. R. McLaughlin, J. Green, H. B. Younghusband, and M. O. Woods Cytochrome P450 17A1 and Catechol O-Methyltransferase Polymorphisms and Age at Lynch Syndrome Colon Cancer Onset in Newfoundland Clin. Cancer Res., July 1, 2007; 13(13): 3783 - 3788. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Henningson, U. Johansson, A. Borg, H. Olsson, and H. Jernstrom CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women Mol. Hum. Reprod., April 1, 2007; 13(4): 231 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Olson, E. V. Bandera, and I. Orlow Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Jasienska, M. Kapiszewska, P. T. Ellison, M. Kalemba-Drozdz, I. Nenko, I. Thune, and A. Ziomkiewicz CYP17 Genotypes Differ in Salivary 17-{beta} Estradiol Levels: A Study Based on Hormonal Profiles from Entire Menstrual Cycles. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2131 - 2135. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Nathan, C. A. Hodges, P. J. Supelak, L. C. Burrage, J. H. Nadeau, and M. R. Palmert A Quantitative Trait Locus on Chromosome 6 Regulates the Onset of Puberty in Mice Endocrinology, November 1, 2006; 147(11): 5132 - 5138. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. Setiawan, C. A. Haiman, F. Z. Stanczyk, L. Le Marchand, and B. E. Henderson Racial/Ethnic differences in postmenopausal endogenous hormones: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1849 - 1855. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Piller, E. Verla-Tebit, S. Wang-Gohrke, J. Linseisen, and J. Chang-Claude CYP17 Genotype Modifies the Association between Lignan Supply and Premenopausal Breast Cancer Risk in Humans J. Nutr., June 1, 2006; 136(6): 1596 - 1603. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Huggins, J. Y.Y. Wong, S. E. Hankinson, and I. De Vivo GATA5 Activation of the Progesterone Receptor Gene Promoter in Breast Cancer Cells Is Influenced by the +331G/A Polymorphism Cancer Res., February 1, 2006; 66(3): 1384 - 1390. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lurie, G. Maskarinec, R. Kaaks, F. Z. Stanczyk, and L. Le Marchand Association of Genetic Polymorphisms with Serum Estrogens Measured Multiple Times During a 2-Year Period in Premenopausal Women Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1521 - 1527. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Xita, A. Tsatsoulis, I. Stavrou, and I. Georgiou Association of SHBG gene polymorphism with menarche Mol. Hum. Reprod., June 1, 2005; 11(6): 459 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C. Onland-Moret, C. H. van Gils, M. Roest, D. E. Grobbee, and P. H.M. Peeters Cyp17, Urinary Sex Steroid Levels and Breast Cancer Risk in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 815 - 820. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Kok, N. C. Onland-Moret, K. M. van Asselt, C. H. van Gils, Y. T. van der Schouw, D. E. Grobbee, and P. H.M. Peeters No association of estrogen receptor {alpha} and cytochrome P450c17{alpha} polymorphisms with age at menopause in a Dutch cohort Hum. Reprod., February 1, 2005; 20(2): 536 - 542. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Travis, M. Churchman, S. A. Edwards, G. Smith, P. K. Verkasalo, C. R. Wolf, H. Wolf, and T. J. Key No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2282 - 2284. [Full Text] [PDF] |
||||
![]() |
L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Dunning, M. Dowsett, C. S. Healey, L. Tee, R. N. Luben, E. Folkerd, K. L. Novik, L. Kelemen, S. Ogata, P. D. P. Pharoah, et al. Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women J Natl Cancer Inst, June 16, 2004; 96(12): 936 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. Setiawan, S. E. Hankinson, G. A. Colditz, D. J. Hunter, and I. De Vivo HSD17B1 Gene Polymorphisms and Risk of Endometrial and Breast Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 213 - 219. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Han, S. E. Hankinson, H. Ranu, I. De Vivo, and D. J. Hunter Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study Carcinogenesis, February 1, 2004; 25(2): 189 - 195. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Tworoger, J. Chubak, E. J. Aiello, C. M. Ulrich, C. Atkinson, J. D. Potter, Y. Yasui, P. L. Stapleton, J. W. Lampe, F. M. Farin, et al. Association of CYP17, CYP19, CYP1B1, and COMT Polymorphisms with Serum and Urinary Sex Hormone Concentrations in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 94 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamada, F. Sata, E. H. Kato, Y. Saijo, S. Kataoka, M. Morikawa, S. Shimada, T. Yamada, R. Kishi, and H. Minakami A polymorphism in the CYP17 gene and intrauterine fetal growth restriction Mol. Hum. Reprod., January 1, 2004; 10(1): 49 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Sata, H. Yamada, A. Yamada, E. H. Kato, S. Kataoka, Y. Saijo, T. Kondo, J. Tamaki, H. Minakami, and R. Kishi A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss Mol. Hum. Reprod., November 1, 2003; 9(11): 725 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. De Vivo, S. E. Hankinson, G. A. Colditz, and D. J. Hunter A Functional Polymorphism in the Progesterone Receptor Gene Is Associated with an Increase in Breast Cancer Risk Cancer Res., September 1, 2003; 63(17): 5236 - 5238. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ahsan and A. G. Rundle Measures of genotype versus gene products: promise and pitfalls in cancer prevention Carcinogenesis, September 1, 2003; 24(9): 1429 - 1434. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ntais, A. Polycarpou, and J. P. A. Ioannidis Association of the CYP17 Gene Polymorphism with the Risk of Prostate Cancer: A Meta-Analysis Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 120 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Gorai, K. Tanaka, M. Inada, H. Morinaga, Y. Uchiyama, R. Kikuchi, O. Chaki, and F. Hirahara Estrogen-Metabolizing Gene Polymorphisms, But Not Estrogen Receptor-{alpha} Gene Polymorphisms, Are Associated with the Onset of Menarche in Healthy Postmenopausal Japanese Women J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 799 - 803. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. McCann, K. B. Moysich, J. L. Freudenheim, C. B. Ambrosone, and P. G. Shields The Risk of Breast Cancer Associated with Dietary Lignans Differs by CYP17 Genotype in Women J. Nutr., October 1, 2002; 132(10): 3036 - 3041. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Feigelson, R. McKean-Cowdin, and B. E. Henderson Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, September 1, 2002; 17(5): 445 - 446. [Full Text] [PDF] |
||||
![]() |
E. I. O. Garner, E. E. Stokes, R. S. Berkowitz, S. C. Mok, and D. W. Cramer Polymorphisms of the Estrogen-metabolizing Genes CYP17 and Catechol-O-methyltransferase and Risk of Epithelial Ovarian Cancer Cancer Res., June 1, 2002; 62(11): 3058 - 3062. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. De Vivo, S. E. Hankinson, L. Li, G. A. Colditz, and D. J. Hunter Association of CYP1B1 Polymorphisms and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 489 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kado, J. Kitawaki, H. Obayashi, H. Ishihara, H. Koshiba, I. Kusuki, K. Tsukamoto, G. Hasegawa, N. Nakamura, T. Yoshikawa, et al. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women Hum. Reprod., April 1, 2002; 17(4): 897 - 902. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Stavrou, C. Zois, J.P.A. Ioannidis, and A. Tsatsoulis Association of polymorphisms of the oestrogen receptor{alpha} gene with the age of menarche Hum. Reprod., April 1, 2002; 17(4): 1101 - 1105. [Abstract] [Full Text] [PDF] |
||||
![]() |
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility J. Med. Genet., April 1, 2002; 39(4): 225 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ye and J. M. Parry The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, March 1, 2002; 17(2): 119 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-W. Yu, Y.-C. Yang, S.-Y. Yang, S.-W. Cheng, Y.-F. Liaw, S.-M. Lin, and C.-J. Chen Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case-Control Study Among Men J Natl Cancer Inst, November 7, 2001; 93(21): 1644 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Haiman, M. J. Stampfer, E. Giovannucci, J. Ma, N. E. Decalo, P. W. Kantoff, and D. J. Hunter The Relationship between a Polymorphism in CYP17 with Plasma Hormone Levels and Prostate Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 743 - 748. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Armstrong Genetic Susceptibility to Breast Cancer: From the Roll of the Dice to the Hand Women Were Dealt JAMA, June 13, 2001; 285(22): 2907 - 2909. [Full Text] [PDF] |
||||
![]() |
C. Guillemette, I. De Vivo, S. E. Hankinson, C. A. Haiman, D. Spiegelman, D. E. Housman, and D. J. Hunter Association of Genetic Polymorphisms in UGT1A1 with Breast Cancer and Plasma Hormone Levels Cancer Epidemiol. Biomarkers Prev., June 1, 2001; 10(6): 711 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Goodman, K. McDuffie, C. Guo, K. Terada, and T. A. Donlon CYP17 Genotype and Ovarian Cancer: A Null Case-Control Study Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 563 - 564. [Full Text] |
||||
![]() |
C. A. Haiman, S. E. Hankinson, G. A. Colditz, D. J. Hunter, and I. De Vivo A Polymorphism in CYP17 and Endometrial Cancer Risk Cancer Res., May 1, 2001; 61(10): 3955 - 3960. [Abstract] [Full Text] |
||||
![]() |
N. E. Allen, M. S. Forrest, and T. J. Key The Association between Polymorphisms in the CYP17 and 5{{alpha}}-Reductase (SRD5A2) Genes and Serum Androgen Concentrations in Men Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 185 - 189. [Abstract] [Full Text] |
||||
![]() |
L. M. Hines, M. J. Stampfer, J. Ma, J. M. Gaziano, P. M. Ridker, S. E. Hankinson, F. Sacks, E. B. Rimm, and D. J. Hunter Genetic Variation in Alcohol Dehydrogenase and the Beneficial Effect of Moderate Alcohol Consumption on Myocardial Infarction N. Engl. J. Med., February 22, 2001; 344(8): 549 - 555. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. McKean-Cowdin, H. S. Feigelson, M. C. Pike, G. A. Coetzee, L. N. Kolonel, and B. E. Henderson Risk of Endometrial Cancer and Estrogen Replacement Therapy History by CYP17 Genotype Cancer Res., February 1, 2001; 61(3): 848 - 849. [Abstract] [Full Text] |
||||
![]() |
M. Clemons and P. Goss Estrogen and the Risk of Breast Cancer N. Engl. J. Med., January 25, 2001; 344(4): 276 - 285. [Full Text] [PDF] |
||||
![]() |
H. S. Feigelson, R. McKean-Cowdin, G. A. Coetzee, D. O. Stram, L. N. Kolonel, and B. E. Henderson Building a Multigenic Model of Breast Cancer Susceptibility: CYP17 and HSD17B1 Are Two Important Candidates Cancer Res., January 1, 2001; 61(2): 785 - 789. [Abstract] [Full Text] |
||||
![]() |
K. Mitrunen, N. Jourenkova, V. Kataja, M. Eskelinen, V.-M. Kosma, S. Benhamou, H. Vainio, M. Uusitupa, and A. Hirvonen Steroid Metabolism Gene CYP17 Polymorphism and the Development of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1343 - 1348. [Abstract] [Full Text] |
||||
![]() |
A. B. Spurdle, J. L. Hopper, G. S. Dite, X. Chen, J. Cui, M. R. E. McCredie, G. G. Giles, M. C. Southey, D. J. Venter, D. F. Easton, et al. CYP17 Promoter Polymorphism and Breast Cancer in Australian Women Under Age Forty Years J Natl Cancer Inst, October 18, 2000; 92(20): 1674 - 1681. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Habuchi, Z. Liqing, T. Suzuki, R. Sasaki, N. Tsuchiya, H. Tachiki, N. Shimoda, S. Satoh, K. Sato, Y. Kakehi, et al. Increased Risk of Prostate Cancer and Benign Prostatic Hyperplasia Associated with a CYP17 Gene Polymorphism with a Gene Dosage Effect Cancer Res., October 1, 2000; 60(20): 5710 - 5713. [Abstract] [Full Text] |
||||
![]() |
M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Thompson and C. Ambrosone Chapter 7: Molecular Epidemiology of Genetic Polymorphisms in Estrogen Metabolizing Enzymes in Human Breast Cancer J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 125 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. E. Henderson and H. S. Feigelson Hormonal carcinogenesis Carcinogenesis, March 1, 2000; 21(3): 427 - 433. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guillemette, R. C. Millikan, B. Newman, and D. E. Housman Genetic Polymorphisms in Uridine Diphospho-Glucuronosyltransferase 1A1 and Association with Breast Cancer among African Americans Cancer Res., February 1, 2000; 60(4): 950 - 956. [Abstract] [Full Text] |
||||
![]() |
H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28. [Abstract] [Full Text] |
||||
![]() |
S. S. Coughlin and M. Piper Genetic Polymorphisms and Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 1999; 8(11): 1023 - 1032. [Full Text] |
||||
![]() |
H. S. Feigelson, R. McKean-Cowdin, M. C. Pike, G. A. Coetzee, L. N. Kolonel, A. M. Y. Nomura, L. L. Marchand, and B. E. Henderson Cytochrome P450c17{{alpha}} Gene (CYP17) Polymorphism Predicts Use of Hormone Replacement Therapy Cancer Res., August 1, 1999; 59(16): 3908 - 3910. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |